Avid Bioservices Inc (CDMO)

[sulaco]

GARNICK SPEAKS 3/12/2013 CC

"...as I point out to many people, there are very few and far between Phase II trials that ever show statistical significance and efficacy. That's an absolutely unbelievable hurdle for a Phase II product.

And what you're really looking for is a ability to describe that you do have clinical efficacy. And as Joe had said, showing 11.7 months for the 3-milligram arm and a difference in the pooled dataset for the product of 7.3 months when you combine the control and the placebo, definitely gives you the indication that in overall survival, we have a potentially highly efficacious product."